12.07.2016 • News • Elaine Burridge • Alfred Talke • Antwerp

Talke Sells Logistics Assets to Katoen Natie

Port of Antwerp
Port of Antwerp

German chemical logistics operator Talke has sold its sites and activities in Antwerp, Belgium, and Moerdijk, the Netherlands, to Katoen Natie. Financial details of the transaction were not disclosed.

Talke said the sale is part of a program to divest subsidiaries that no longer fit into its strategy as it optimizes its portfolio of locations. At the same time, it said it wanted to focus more intensively on its business in other parts of Europe, the Middle East, Asia and the US.

Privately held Katoen Natie is headquartered in Antwerp, Belgium, and operates 150 terminals or logistics platforms around the world.

Company

Logo:

Alfred Talke GmbH & Co. KG

Max-Planck-Strasse 20
50354 Hürth
Germany

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.